AstraZeneca PLC (AZN)

Check out top investors' recommendation for AZN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a licensing agreement with Ardelyx, Inc. with respect to NHE3 inhibitor program for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD); and a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Alex Arfaei BMO Capital Markets Buy   Jan 10, '18     38.00  Jan 10, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Oct 31, '17     38.00  Oct 31, '18  N/A 
Andrew Baum Citi Buy   Oct 18, '17       Oct 18, '18  N/A 
Tim Anderson High Peaks Buy   Sep 22, '17     39.00  Sep 22, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Sep 06, '17     38.00  Sep 06, '18  N/A 
Richard Purkiss Atlantic Equities Buy   Aug 09, '17       Aug 09, '18  N/A 
Seamus Fernandez Leerink Swann Llc Buy   Jul 14, '17     36.00  Jul 14, '18  N/A 
Seamus Fernandez Leerink Swann Llc Buy   May 16, '17     36.00  May 16, '18  N/A 
Brian White Topeka Capital Markets Buy   Feb 26, '16   28.05    Feb 26, '17  N/A 
Mark Clark Deutsche Bank Securities Buy   Sep 14, '15   31.71    Sep 14, '16  N/A 
Vamil Divan Credit Suisse Buy   Apr 24, '15   34.31    Apr 24, '16  -12.27% 
Savvas Neophytou Panmure Gordon & Co. Limited Buy   Oct 07, '14   33.13    Oct 07, '15  -3.17% 
Alexandra Hauber JPMorgan Sell   Jul 03, '14   72.62    Jul 03, '15  9.93% 
Savvas Neophytou Panmure Gordon & Co. Limited Buy   Apr 29, '14   74.03    Apr 29, '15  -5.51% 
Alexandra Hauber JPMorgan Sell   Mar 13, '14   62.66    Mar 13, '15  -6.69% 
Savvas Neophytou Panmure Gordon & Co. Limited Sell   Nov 13, '13   50.53    Nov 13, '14  -46.96%